ABBV vs SLP
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.
Simulations Plus (SLP) exhibits severe fundamental weakness, highlighted by a Piotroski F-Score of 2/9, indicating a deteriorating financial trend. While the company maintains an exceptionally clean balance sheet with zero debt and high liquidity (Current Ratio 5.47), this is offset by a disastrous profit margin of -77.96% and a long-term price collapse of -76.6% over five years. The valuation is problematic, with a PEG ratio of 9.88 suggesting the stock is significantly overvalued relative to its growth. Despite optimistic analyst price targets, the deterministic data and bearish insider sentiment point to continued instability.
Compare Another Pair
Related Comparisons
ABBV vs SLP: Head-to-Head Comparison
This page compares AbbVie Inc. (ABBV) and Simulations Plus, Inc. (SLP) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.